The EC granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union Vueway®, a new macrocyclic gadolinium-based contrast agent for CE-MRI, received Marketing Authorisation in the European Union By European Commission.

Europäische Kommission erteilt Marktzulassung für Vueway® (Gadopiclenol) Die Europäische Kommission hat am 7. Dezember 2023 die Marktzulassung für das MR-Kontrastmittel Vueway® (Gadopiclenol) von Bracco Imaging S.p.A. erteilt.

Vueway® (Gadopiclenol) Vueway® (Gadopiclenol) ist ein hochstabiles makrozyklisches MRT Kontrastmittel. Finden Sie weitere Fachinformationen auf dieser Seite.

Bracco @ ECR

The future in MRI: Vueway® Erfahren Sie mehr über das innovative MRT-Kontrastmittel Vueway® und über die ersten Erfahrungen in der täglichen Anwendung.

Samsung Medison and Bracco Imaging announce a new agreement Samsung Medison and Bracco Imaging endorsed a Memorandum of Understanding agreement to pioneer a new area for diagnostic ultrasound device and contrast agent at European Congress of Radiology 2024 held in Vienna, Austria on February 28th to March 3rd.

Ulm-Augsburger Radiologisches Sommer-Symposium

The Bracco Group announces the newly-created Bracco Japan The Bracco Group announces its direct presence in the Japanese market, where it has been doing business since 1990 through a successful joint venture with Eisai

Bracco Suisse and Verasonics: a new strategic partnership The collaboration focuses on combining Verasonics' Vantage®️ NXT Research Ultrasound Systems with Bracco's contrast agents to explore improved imaging performance in various research applications.

Blue Earth Diagnostics appoints Marco Campione as Chief Executive Officer Mr. Campione brings more than 25 years global experience in successful development and commercialization of diagnostic imaging agents and radiopharmaceuticals.